1102657 Stock Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 6/6 |
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£26.12 |
| 52 Week High | UK£27.51 |
| 52 Week Low | UK£25.00 |
| Beta | 0.25 |
| 1 Month Change | -2.48% |
| 3 Month Change | n/a |
| 1 Year Change | -2.83% |
| 3 Year Change | 5.63% |
| 5 Year Change | 6.81% |
| Change since IPO | 3.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1102657 | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -0.9% |
| 1Y | -2.8% | -13.1% | -4.0% |
Return vs Industry: 001102657 exceeded the Swiss Pharmaceuticals industry which returned -9.5% over the past year.
Return vs Market: 001102657 underperformed the Swiss Market which returned -0.9% over the past year.
Price Volatility
| 1102657 volatility | |
|---|---|
| 1102657 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 3.3% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: 001102657 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 001102657's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 90,096 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
GSK plc Fundamentals Summary
| 1102657 fundamental statistics | |
|---|---|
| Market cap | CHF81.59b |
| Earnings (TTM) | CHF5.91b |
| Revenue (TTM) | CHF42.17b |
13.8x
P/E Ratio1.9x
P/S RatioIs 1102657 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1102657 income statement (TTM) | |
|---|---|
| Revenue | UK£36.48b |
| Cost of Revenue | UK£12.66b |
| Gross Profit | UK£23.82b |
| Other Expenses | UK£18.70b |
| Earnings | UK£5.11b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 27, 2022
| Earnings per share (EPS) | 1.26 |
| Gross Margin | 65.29% |
| Net Profit Margin | 14.02% |
| Debt/Equity Ratio | 147.4% |
How did 1102657 perform over the long term?
See historical performance and comparison